ABBV-011 — Investigational Agent
Antibody-Drug Conjugate · Phase 1 · AbbVie
Mechanism of Action
Antibody-drug conjugate targeting SEZ6, a surface antigen frequently expressed in small cell lung cancer, linked via a non-cleavable linker to a calicheamicin payload that induces DNA double-strand breaks and apoptosis in antigen-expressing tumor cells.
Investigational Indications
- Small cell lung cancer
- SEZ6-expressing neuroendocrine tumors